- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: example 60 [WO2007075567A1] | JNJ-38877618 | JNJ38877618 | OMO1
Compound class: Synthetic organic
Comment: OMO-1 (formerly JNJ-38877618) is a potent, highly selective and orally bioavailable MET kinase inhibitor. It is being investigated as an anti-tumour agent in advanced solid malignancies. The chemical structure of OMO-1 is one of those claimed in Janssen patent WO2007075567A1 .
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Lu T, Alexander R, Connors RW, Cummings MD, Galemmo RA, Hufnagel HR, Johnson DL, Khalil E, Leonard KA, Markotan TP et al.. (2007)
Triazolopyridazines as tyrosine kinase modulators.
Patent number: WO2007075567A1. Assignee: Janssen Pharmaceutica, N.V.. Priority date: 21/12/2005. Publication date: 05/07/2007.